EPA:ALCJ - Euronext Paris - Matif - FR0011716265 - Common Stock - Currency: EUR
EPA:ALCJ (3/7/2025, 7:00:00 PM)
1.97
+0.01 (+0.41%)
The current stock price of ALCJ.PA is 1.97 EUR. In the past month the price increased by 4.56%. In the past year, price decreased by -42.73%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
EL.PA | ESSILORLUXOTTICA | 53.13 | 124.44B | ||
ESL.DE | ESSILORLUXOTTICA | 53.09 | 124.35B | ||
1EL.MI | ESSILORLUXOTTICA | 52.97 | 124.08B | ||
CBHD.DE | COLOPLAST-B | 33.98 | 21.00B | ||
GENT.OL | GENTIAN DIAGNOSTICS ASA | 16.31 | 721.66M | ||
GBT.PA | GUERBET | 10.23 | 341.28M | ||
PTP.DE | PENTIXAPHARM HOLDING AG | N/A | 89.03M | ||
AFME.PA | AFFLUENT MEDICAL SA | N/A | 55.09M | ||
SVS.MI | SVAS BIOSANA SPA | 7.25 | 41.44M | ||
IVN.MI | IVISION TECH SPA | N/A | 16.85M |
Crossject SA manufactures and markets needle free injection system. The company is headquartered in Dijon, Bourgogne-Franche-Comte and currently employs 110 full-time employees. The company went IPO on 2014-02-20. The firm specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous, and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The firm's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance, and comfort. The firm has industrial partnerships with Hirtenberger and Recipharm. The company provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
CROSSJECT
Parc Mazen-Sully, 6 Rue Pauline Kergomard
Dijon BOURGOGNE-FRANCHE-COMTE FR
Employees: 105
Company Website: https://www.crossject.com
Investor Relations: http://www.crossject.com/rapports-financiers-et-documents-de-r%C3%A9f%C3%A9rence/
Phone: 33380549850
The current stock price of ALCJ.PA is 1.97 EUR. The price increased by 0.41% in the last trading session.
The exchange symbol of CROSSJECT is ALCJ and it is listed on the Euronext Paris - Matif exchange.
ALCJ.PA stock is listed on the Euronext Paris - Matif exchange.
9 analysts have analysed ALCJ.PA and the average price target is 4.13 EUR. This implies a price increase of 109.7% is expected in the next year compared to the current price of 1.97. Check the CROSSJECT stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CROSSJECT (ALCJ.PA) has a market capitalization of 91.07M EUR. This makes ALCJ.PA a Micro Cap stock.
CROSSJECT (ALCJ.PA) currently has 105 employees.
CROSSJECT (ALCJ.PA) has a support level at 1.78 and a resistance level at 2.18. Check the full technical report for a detailed analysis of ALCJ.PA support and resistance levels.
The Revenue of CROSSJECT (ALCJ.PA) is expected to grow by 3.06% in the next year. Check the estimates tab for more information on the ALCJ.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALCJ.PA does not pay a dividend.
CROSSJECT (ALCJ.PA) will report earnings on 2025-03-31, after the market close.
CROSSJECT (ALCJ.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.26).
ChartMill assigns a technical rating of 2 / 10 to ALCJ.PA. When comparing the yearly performance of all stocks, ALCJ.PA is a bad performer in the overall market: 93.92% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to ALCJ.PA. Both the profitability and financial health of ALCJ.PA have multiple concerns.
Over the last trailing twelve months ALCJ.PA reported a non-GAAP Earnings per Share(EPS) of -0.26. The EPS decreased by -1.92% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -31.63% | ||
ROE | -593.99% | ||
Debt/Equity | 11.67 |
ChartMill assigns a Buy % Consensus number of 84% to ALCJ.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 33.19% and a revenue growth 3.06% for ALCJ.PA